ATE101796T1 - Blutgerinnungshemmende zusammensetzungen aus faktor xa. - Google Patents
Blutgerinnungshemmende zusammensetzungen aus faktor xa.Info
- Publication number
- ATE101796T1 ATE101796T1 AT90909958T AT90909958T ATE101796T1 AT E101796 T1 ATE101796 T1 AT E101796T1 AT 90909958 T AT90909958 T AT 90909958T AT 90909958 T AT90909958 T AT 90909958T AT E101796 T1 ATE101796 T1 AT E101796T1
- Authority
- AT
- Austria
- Prior art keywords
- factor
- inactivated
- vivo
- active
- serine
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 abstract 5
- 238000001727 in vivo Methods 0.000 abstract 3
- 108010074105 Factor Va Proteins 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 230000015271 coagulation Effects 0.000 abstract 2
- 238000005345 coagulation Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- LDMSFLLWFAFZAF-OALUTQOASA-N (4s)-5-[[2-[[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-2-oxoethyl]amino]-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl LDMSFLLWFAFZAF-OALUTQOASA-N 0.000 abstract 1
- 102100027378 Prothrombin Human genes 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940039716 prothrombin Drugs 0.000 abstract 1
- 108020002447 serine esterase Proteins 0.000 abstract 1
- 102000005428 serine esterase Human genes 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/367,544 US5120537A (en) | 1989-06-14 | 1989-06-14 | Factor xa based anticoagulant compositions |
| PCT/US1990/003208 WO1990015619A1 (en) | 1989-06-14 | 1990-06-06 | FACTOR Xa BASED ANTICOAGULANT COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE101796T1 true ATE101796T1 (de) | 1994-03-15 |
Family
ID=23447608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90909958T ATE101796T1 (de) | 1989-06-14 | 1990-06-06 | Blutgerinnungshemmende zusammensetzungen aus faktor xa. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5120537A (de) |
| EP (1) | EP0477274B1 (de) |
| JP (1) | JPH0784392B2 (de) |
| AT (1) | ATE101796T1 (de) |
| AU (1) | AU630477B2 (de) |
| CA (1) | CA2060507C (de) |
| DE (1) | DE69006851T2 (de) |
| DK (1) | DK0477274T3 (de) |
| ES (1) | ES2063365T3 (de) |
| WO (1) | WO1990015619A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS136091A3 (en) * | 1990-05-10 | 1992-04-15 | Zymo Genetics | Agents for determining thrombi and their application |
| US20040072757A1 (en) * | 1990-09-04 | 2004-04-15 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5597799A (en) * | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| US5278144A (en) * | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| WO1993007491A1 (en) * | 1991-10-04 | 1993-04-15 | Board Of Regents Of The University Of Nebraska | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
| US5716795A (en) * | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
| US6039944A (en) * | 1992-02-28 | 2000-03-21 | Zymogenetics, Inc. | Modified Factor VII |
| US5266462A (en) * | 1992-06-03 | 1993-11-30 | Baxter Diagnostics Inc. | Measurement of platelet activities |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| HUP9700603A3 (en) * | 1996-03-20 | 2001-08-28 | Baxter Ag | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| JP4463460B2 (ja) * | 1999-11-02 | 2010-05-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｘａ因子阻害剤の活性をモニターするためラッセルクサリヘビ蛇毒誘導血漿Ｘａ因子活性の使用 |
| AU2001257893A1 (en) * | 2000-01-13 | 2001-07-24 | Baxter International Inc. | Multiple inactivated blood factor anticoagulant composition |
| WO2003055473A1 (en) * | 2001-12-21 | 2003-07-10 | Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center | Regulation of nad(p)h oxidase growth and transcription in melanoma cells |
| US7354897B2 (en) * | 2002-06-07 | 2008-04-08 | Brigham & Women's Hospital, Inc. | Method and composition for inhibiting or slowing blood coagulation |
| WO2005005954A2 (en) * | 2003-06-30 | 2005-01-20 | The Brigham & Women's Hospital, Inc. | Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes |
| US9956272B2 (en) | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
| GB0710321D0 (en) * | 2007-05-30 | 2007-07-11 | Nhs Blood & Transplant | Method |
| PT3078743T (pt) * | 2007-09-28 | 2020-07-15 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
| ES3020087T3 (en) | 2020-09-21 | 2025-05-21 | Instr Laboratory Co | Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample |
| CN119095400B (zh) * | 2023-06-06 | 2025-10-03 | 华能新能源股份有限公司 | 一种钙钛矿太阳能电池及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| DE3688983T2 (de) * | 1985-03-15 | 1994-02-17 | British Tech Group | Faktor IX-Protein. |
| US4832849A (en) * | 1988-06-16 | 1989-05-23 | Merrell Dow Pharmaceuticals Inc. | Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii |
-
1989
- 1989-06-14 US US07/367,544 patent/US5120537A/en not_active Expired - Lifetime
-
1990
- 1990-06-06 ES ES90909958T patent/ES2063365T3/es not_active Expired - Lifetime
- 1990-06-06 JP JP2509853A patent/JPH0784392B2/ja not_active Expired - Fee Related
- 1990-06-06 EP EP90909958A patent/EP0477274B1/de not_active Expired - Lifetime
- 1990-06-06 DK DK90909958.2T patent/DK0477274T3/da active
- 1990-06-06 WO PCT/US1990/003208 patent/WO1990015619A1/en not_active Ceased
- 1990-06-06 AU AU59226/90A patent/AU630477B2/en not_active Ceased
- 1990-06-06 CA CA002060507A patent/CA2060507C/en not_active Expired - Fee Related
- 1990-06-06 DE DE69006851T patent/DE69006851T2/de not_active Expired - Fee Related
- 1990-06-06 AT AT90909958T patent/ATE101796T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0784392B2 (ja) | 1995-09-13 |
| DE69006851T2 (de) | 1994-06-30 |
| DK0477274T3 (da) | 1994-03-28 |
| ES2063365T3 (es) | 1995-01-01 |
| AU5922690A (en) | 1991-01-08 |
| EP0477274B1 (de) | 1994-02-23 |
| WO1990015619A1 (en) | 1990-12-27 |
| CA2060507C (en) | 1996-12-10 |
| DE69006851D1 (de) | 1994-03-31 |
| AU630477B2 (en) | 1992-10-29 |
| EP0477274A1 (de) | 1992-04-01 |
| US5120537A (en) | 1992-06-09 |
| CA2060507A1 (en) | 1990-12-15 |
| JPH04505765A (ja) | 1992-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE101796T1 (de) | Blutgerinnungshemmende zusammensetzungen aus faktor xa. | |
| Rajesh et al. | Procoagulant activity of Calotropis gigantea latex associated with fibrin (ogen) olytic activity | |
| Bell Jr | Defibrinogenating enzymes | |
| Hedner et al. | Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. | |
| Himber et al. | Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function | |
| DE69131292D1 (de) | Antikoagulierende proteine | |
| ES2018729A6 (es) | Un metodo para preparar una variante de activador de plasmogeno de tejido. | |
| Thakur et al. | A brief appraisal on Russell’s viper venom (Daboia russelii russelii) proteinases | |
| SAWYER et al. | Thrombolytic therapy: basic and therapeutic considerations | |
| Kini et al. | Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation | |
| Glazer et al. | Clinical update on the use of recombinant factor VII | |
| Aronson | Factor IX complex | |
| Briet et al. | Cleavage and activation of human prothrombin by Echiscarinatus venom | |
| DE59002760D1 (de) | K2p pro-stabilisierung. | |
| DE69632629D1 (de) | Thrombin zusammensetzung | |
| Grotto et al. | Effect of purified Vipera palestinae hemorrhagin on blood coagulation and platelet function | |
| Weinstein et al. | Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction. | |
| McNicol | Disordered fibrinolytic activity and its control | |
| Kazama et al. | Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4: role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein | |
| Albertini et al. | Experiences with recombinant factor VIIa in haemophiliacs | |
| FI913909A0 (fi) | t-PA pro:n stabilointi | |
| Chang et al. | The reaction of thrombin with platelet-derived nexin requires a secondary recognition site in addition to the catalytic site | |
| RU2074709C1 (ru) | Состав для лечения гнойно-трофических язв и пролежней | |
| Ries et al. | Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with α2-antiplasmin | |
| Choi et al. | Undariase, a direct-acting fibrin (ogen) olytic enzyme from Undaria pinnatifida, inhibits thrombosis in vivo and exhibits in vitro thrombolytic properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |